DaVita DVA

Reference table

1. What it is

DaVita Inc. (NYSE: DVA) is a Denver-based kidney-care company and one of the two dominant U.S. dialysis providers (with Fresenius Medical Care). It treats patients with end-stage renal disease (ESRD) through a network of outpatient centers, home-dialysis programs, and hospital inpatient services, and it runs its own labs and a growing integrated kidney care (IKC) value-based-care business. As of Q1'26 it served ~296,300 patients across 3,262 centers (2,666 U.S. / 596 in 14 other countries). Founded 1994; ~76,000 employees; CEO Javier Rodriguez. Fiscal year ends December 31.

Revenue mix (FY2025, from FMP segmentation):

• By segment: essentially all revenue is U.S. Dialysis & Related Lab Services — $11.73B of $13.64B (86%); the remainder is "other" (international dialysis + IKC + ancillary). FMP does not break international/IKC out separately in FY25.
• By geography: FMP provides no geographic split for DVA (seg_geo empty). Per filings the business is overwhelmingly U.S., with a smaller international dialysis footprint across 14 countries.

The structural economics to understand: a large share of profit comes from commercially-insured patients, whose reimbursement rates far exceed the Medicare rates that cover the majority of dialysis patients. This "commercial mix" is the profit engine — and its single greatest vulnerability (§11).

2. The expert thesis (no KB coverage)

There is no expert coverage for DVA in the Synthos knowledge base — total_claims = 0, zero net-bullish voices, zero traceable claim_ids. Unlike our conviction-track names (e.g. LLY, carried by a broad expert panel), this note makes no appeal to expert conviction. The verdict below is built entirely from reported fundamentals, live analyst estimates, valuation, and technicals. Where we state a forward number it is labeled an estimate; nothing here is fabricated conviction. Read the scores in §3 as a quant/fundamental judgment, not a distilled expert consensus.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.

Synthos fair value = the base case, ~$205 (−13%), with the full $150–$265 span as the honest range. Our anchor sits essentially on top of the Street's $202.25 consensus — and, notably, the current price ($234.91) is above the Street's high target ($220). That is the crux of the Watch call: the fundamentals justify a fair, not a premium, multiple, and the market has already paid up. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). DVA is neither a fast compounder nor an exponential — it is a mature, levered cash cow returning capital via buyback:

• Forward growth: revenue CAGR FY25→FY29E ~3.9% ($13.6B → $15.9B, est.). EPS grows faster (FY25 diluted $9.51 → FY28E ~$18.95, est., ~26% CAGR) almost entirely because the share count is collapsing — not because the business is compounding.
• Acceleration (2nd derivative): roughly flat-to-negative. U.S. dialysis treatment growth was ~0.1% YoY in Q1'26 and revenue-per-treatment actually fell QoQ ($422.60 → $417.59). There is no top-line inflection to point to.
• Room to run: the U.S. dialysis TAM is mature and largely penetrated — DaVita and Fresenius already run most of it. The long-run demand curve faces a negative secular force: GLP-1/obesity and diabetes drugs may reduce new-onset ESRD over the next decade. Market cap $15B is small, but the addressable pool is not expanding.
• Reinvestment runway: capex is maintenance-heavy (~$576M/yr, ~29% of operating cash flow); excess FCF goes to buybacks, not high-return growth projects. That's rational for a mature operator — but it is the signature of a value/return-of-capital name, not an exponential.

Exponential Potential: Low (2/10). Own DVA, if at all, for steady FCF and float-shrink — never for a fast multibagger. Honest framing places it firmly outside any growth or "next-exponential" sleeve.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 $13.64B, +6.5% (FY24 $12.82B, +5.6% on FY23 $12.14B). Low-single-to-mid-single-digit grower.
• Quarterly trajectory: Q1'25 $3.22B → Q2 $3.38B → Q3 $3.42B → Q4 $3.62B → Q1'26 $3.42B (+5.9% YoY). Steady, not accelerating.
• Margins: gross 31.1% TTM, EBITDA 19.4%, operating ~15%, net ~5.6% TTM. Operating margin was 14.1% in Q1'26 vs 13.6% a year earlier — stable, thin at the bottom line because of heavy interest expense.
• Earnings: FY25 bottom-line net income $721.8M; diluted EPS $9.51 (GAAP). Q1'26 diluted EPS from continuing ops $2.87 (beat the $2.41 estimate). Note the 2025 GAAP net income was depressed by minority-interest and discontinued-ops items; adjusted EPS runs higher (management guides FY26 adjusted EPS to $14.10–$15.20 — see §9).
• Cash flow: FY25 operating CF $1.89B, capex −$576M, FCF $1.31B (~8.7% FCF yield). FCF fully funds the buyback.
• Balance sheet — the risk flag: total debt $15.05B, net debt $14.29B, net-debt/EBITDA 4.6×. Book equity is negative (−$651M) because DaVita has repurchased stock well above book value for years. Interest coverage ~3.7×. This is an investment-grade-ish but genuinely levered balance sheet — fine while cash flow is steady, dangerous if reimbursement turns.

6. Valuation — priced in or room?

DVA is not expensive on forward earnings — 15.8× FY26E and 13.6× FY27E EPS, EV/EBITDA 10.2×, ~8.7% FCF yield — all reasonable for a stable cash generator. The problem is not the multiple; it's the price relative to where the fundamentals and the Street say fair value is. After a +60% 12-month run, the stock at $234.91 sits above the Street's high target ($220) and ~16% above consensus ($202.25). A ~4%-revenue business with 4.6× leverage does not obviously deserve a re-rate from here; the EPS growth that carries the story is buyback-driven, which the market already knows and has arguably front-run. Street targets (context): consensus $202.25, high $220, low $190, rating Hold (9 Buy / 13 Hold / 1 Sell). Our $205 base fair value lands right on consensus. Not a value buy at $235; a wait-for-a-better-entry name.

7. Technicals (from the FMP tech block)

• Trend: strongly up but overextended. $234.91 is at the 52-week high and far above the 50-DMA ($192.86) and 200-DMA ($146.13); the 50 is well above the 200 (golden-cross posture). MACD +9.8 (positive).
• Location: 0% off the 52-week high (i.e. at it), +126% off the 52-week low ($103.87), zero drawdown from peak. A name that has doubled off its low.
• Momentum — the warning: RSI(14) 91 — deeply overbought (anything >70 is stretched; 91 is extreme). This is the single loudest technical signal here: chasing at RSI 91 into a fresh high is a poor risk/reward entry.
• Relative strength: DVA +60% 12-mo vs SPY +20.6%, +56% 3-mo vs SPY +14%. Massive outperformance — which is exactly why it's now stretched.
• Read: technicals contradict a fresh buy. Strong trend, but an RSI-91 blow-off at the highs and above all price targets argues for patience — a mean-reversion toward the rising 50-DMA (~$193) would be a far better risk/reward.

8. Moat & competitive position

DaVita's moat is real and structural: with Fresenius it forms a U.S. dialysis duopoly, benefiting from scale in purchasing and centers, regulatory/accreditation barriers, sticky life-sustaining patient relationships, and the commercial-payer mix that subsidizes lower Medicare rates. Switching costs for patients are high and the service is non-discretionary. The threats are equally structural: reimbursement dependence (Medicare sets the majority rate; Medicare Advantage growth compresses mix), regulatory/legal risk on commercial-vs-Medicare steering, and the GLP-1 secular headwind to long-run ESRD incidence.

Peer set (FMP-supplied, market cap): the list is loosely-comparable healthcare names rather than pure dialysis peers — Molina Healthcare $12.0B, The Ensign Group $9.8B, Universal Health Services $9.9B, Chemed $6.5B, Henry Schein $9.8B, Align Technology $13.2B, Revolution Medicines $40.2B, BioMarin $11.4B, Bio-Rad $8.0B, AptarGroup $8.1B. DVA's truest comp — Fresenius Medical Care — is not in the FMP list; against it DVA is the higher-margin, more buyback-aggressive operator.

9. Management, capital allocation & guidance

• Capital allocation: the defining feature is an aggressive, sustained buyback. Share count has fallen from ~120M (2020) to ~64M today; in Q1'26 alone DaVita repurchased 3.0M shares at ~$133.70, plus another 2.0M through May 5 at ~$149.81 — well below today's $235, i.e. management was buying far cheaper than the current price. No dividend. This is a rational float-shrink strategy that manufactures EPS growth, funded by FCF and some incremental debt (net-debt/EBITDA 4.6×).
• Insider activity: recent Form-4s show selling at these highs — CEO Javier Rodriguez sold ~69,400 shares 2026-06-15/16 around $209, and the Chief Legal Officer sold ~15,400 around $208–209 (2026-06-15). These are officers trimming into strength near current levels; a cluster of sales (not buys) at ~$209 is at least a modest yellow flag given the stock is now higher still at $235.
• Management's own guidance (half-weighted — their book): the Q1'26 earnings release (SEC 8-K / EX-99.1, dated 2026-05-05) raised FY2026 guidance: adjusted diluted EPS from continuing ops $14.10–$15.20 (up from $13.60–$15.00), adjusted operating income $2,150–$2,250M (up from $2,085–$2,235M), and free cash flow $1,000–$1,250M (unchanged). Treat as management's self-interested outlook; note that even the raised EPS midpoint (~$14.65) implies a forward P/E of ~16× at $235, and the growth over FY25 is substantially buyback-aided.

10. Catalysts & what to watch

• Next earnings: 2026-08-05 (Q2'26; Street EPS $3.84, revenue ~$3.50B). Watch revenue-per-treatment (fell QoQ in Q1) and treatment-volume growth (~0.1% YoY — needs to inflect).
• Reimbursement / policy: Medicare base-rate updates and any Medicare Advantage or commercial-steering regulatory/legal developments — the profit-mix lever.
• Buyback pace & leverage: whether management keeps repurchasing (and at what price) and whether net-debt/EBITDA drifts above ~4.6×.
• GLP-1 data: any epidemiological signal that obesity/diabetes drugs are slowing new ESRD onset — the long-run demand question.
• IKC / value-based care: whether integrated kidney care (now ~$5.4B annualized medical spend) becomes a real growth/margin contributor.

Thesis tripwires (what would change the call): a pullback toward the 50-DMA (~$193) or below consensus (~$202) would flip this toward a Buy — Tactical on valuation; conversely, two quarters of negative treatment-volume growth or commercial-mix erosion would push toward Avoid.

11. Key risks

• Valuation/technical (near-term): stock is above every Street target with RSI 91 after a 60% run — poor entry risk/reward.
• Reimbursement & payer mix (structural): profit leans on commercially-insured patients; Medicare Advantage growth and any regulatory limits on commercial steering compress the mix. This is the dominant fundamental risk.
• Leverage: net-debt/EBITDA 4.6× and negative book equity leave little cushion if cash flow softens; rising rates raise the ~$550M/yr interest bill.
• GLP-1/obesity secular headwind: weight-loss/diabetes drugs may reduce long-run new-onset kidney failure, shrinking the future patient pool.
• Volume stagnation: U.S. treatment growth is ~0% and revenue-per-treatment is soft — the organic engine is idling; the story depends on buybacks continuing.
• No expert corroboration: zero Synthos KB coverage — this call has no independent expert panel behind it, only fundamentals/quant.

12. Verdict, position sizing & monitoring

Watch. DaVita is a high-quality, moaty, cash-generative dialysis duopolist — but that is not the question at $234.91. The stock has run +60% in a year to a fresh 52-week high, carries an RSI of 91, trades above every analyst price target, and its earnings growth is manufactured by buybacks on a business growing revenue only ~4% with 4.6× leverage and negative book equity. Our base-case fair value (~$205) sits on the Street consensus and below today's price. There is no expert conviction in the KB to override the quant/valuation read. The honest call is to watch for a better entry, not to chase.

• Sizing: not a fresh-money buy here. If already owned, hold/trim to ≤1–2% and consider harvesting into the strength management itself is selling into. A pullback toward the 50-DMA (~$193) or consensus (~$202) would justify revisiting as Buy — Tactical.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $234.91.
• Single biggest risk: the GLP-1/obesity secular headwind to long-run dialysis demand — a slow but real threat to the terminal patient pool.

Provenance & disclosures

• Traceability: 0 KB claims for DVA (breadth 0, net conviction 0). This note is explicitly fundamentals- and quant-driven; no expert conviction is claimed or fabricated. Claim-ID reconciliation makes fabricated conviction structurally impossible — and here there is simply nothing to cite.
• Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
• Management caveat: DaVita's raised FY26 guidance (adj EPS $14.10–$15.20) is management's own book, half-weighted by design; sourced from the 2026-05-05 SEC 8-K earnings release.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").